Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(T)ides. Biological activities of the resulting adducts
- 1 August 1986
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 29 (8) , 1350-1355
- https://doi.org/10.1021/jm00158a005
Abstract
Note: In lieu of an abstract, this is the article's first page.This publication has 8 references indexed in Scilit:
- Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly a invitroBiochemical and Biophysical Research Communications, 1984
- Potential antitumor agents: synthesis and biological properties of aliphatic amino acid 9-hydroxyellipticinium derivativesJournal of Medicinal Chemistry, 1984
- Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.Proceedings of the National Academy of Sciences, 1984
- IDENTIFICATION OF THE GLUCURONIDE AND GLUTATHIONE CONJUGATES OF THE ANTITUMOR DRUG N2-METHYL-9-HYDROXYELLIPTICINIUM ACETATE (CELIPTIUM) - COMPARATIVE DISPOSITION OF THIS DRUG WITH ITS OLIVACINIUM ISOMER IN RAT BILE1984
- o-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetateJournal of Medicinal Chemistry, 1983
- HYDROXY-9-METHYL-2-ELLIPTICINIUM FOR OSSEOUS METASTASES FROM BREAST-CANCER - A 5-YEAR EXPERIENCE1982
- Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide systemJournal of Medicinal Chemistry, 1981
- Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemiaChemico-Biological Interactions, 1979